t Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 28, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]
Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.
Adcirca is a registered trademark of Eli Lilly and Company.
UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months EndedJune 30,Six Months EndedJune 30,2011201020112010(Unaudited)(Unaudited)Revenues:Net product sales
$
183,546$
134,439$
345,764$
260,071License fees
205282499564Total revenues
183,751134,721346,263260,635Operating expenses:Research and development
24,24028,58771,94763,055Selling, general and administrative
23,85629,65482,11875,106Cost of product sales
21,16215,26140,90028,984Total operating expenses
69,25873,502194,965167,145Operating income
114,49361,219151,29893,490Other (expense) income:Interest income
8398021,5041,746Interest expense
(5,431)(4,759)(10,841)(9,446)Equity loss in affiliate
(30)(44)(67)(91)Other, net
(257)93(1,023)318Total other (expense) income, net
(4,879)(3,908)(10,427)(7,473)Income from continuing operations before income taxes
109,61457,311140,87186,017Income tax expense
(35,723)(19,345)(47,622)(29,106)Income from continuing operations
73,89137,96693,24956,911Discontinued operations:(Loss) income from discontinued operations, net of tax
—(259)76(275)Loss on disposal of discontinued operations, net of tax
——(3,044)—Loss from discontinued operations
—(259)(2,968)(275)N
'/>"/>
SOURCE United Therapeutics Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States2.
Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom3.
United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 20114.
United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial5.
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results6.
United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 20117.
United Therapeutics Corporation Reports Third Quarter 2010 Financial Results8.
United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 20109.
Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma10.
United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 201011.
Report Details How States Respond to Citizens United Decision